in vitro News and Research

RSS

Phadia's ImmunoCAP Rapid System receives FDA marketing clearance

Phadia, the world leader in allergy blood testing diagnostics, today announced that the United States Food and Drug Administration (FDA) has cleared the ImmunoCAP® Rapid Reader II, a part of the ImmunoCAP Rapid System, used to aid in the diagnosis of allergy in the physician’s office.

27 Jan 2010

Dynavax Technologies to present data on its SD-101 Phase 1b trial for chronic HCV infection

Dynavax Technologies Corporation announced today data from two studies that differentiate SD-101 from standard-of-care as well as emerging treatments for chronic HCV infection. The findings of a Phase 1b clinical trial and an in vitro study of SD-101's mechanism of action show that the second-generation TLR9 agonist is well tolerated and safe and induces both IFN-lambda and IFN-alpha at concentrations producing antiviral activity. The data will be presented at the 45th Annual Meeting of the European Association for the Study of the Liver in Vienna, Austria in April 2010.

27 Jan 2010

Long-term graft retention is improved through supplementation of fat grafts with ADRCs

Results from Cytori Therapeutics’ preclinical fat grafting study have been published in the February issue of the Annals of Plastic Surgery. This article, entitled “Supplementation of Fat Grafts with Adipose-Derived Regenerative Cells (ADRCs) Improves Long-Term Graft Retention,” examines the science behind cell-enriched autologous fat grafting and its application to cosmetic and reconstructive surgery. The results demonstrate a doubling in graft retention in cell-enriched grafts and provide insight into the mechanisms behind this improvement.

25 Jan 2010

Heart research news and updates from University of Houston

Matters of the heart dominate in February with Valentine's Day and the American Heart Association's 'Heart Month' topping the list. As you consider story ideas ranging from heart disease to relationships, keep in mind these resources from the University of Houston.

23 Jan 2010

Injectable sealant found to be biocompatible and effective for fetal tissue repair

A sealant inspired by mussels' ability to stick to surfaces under wet conditions has shown promise in the repair of defects in human fetal membranes, according to a recent Northwestern University study.

23 Jan 2010

Findings offer potential significance to the recovery of walking after spinal cord injury

Researchers at the medical university Karolinska Institutet have created a genetically modified mouse in which certain neurons can be activated by blue light. Shining blue light on brainstems or spinal cords isolated from these mice produces walking-like motor activity. The findings, which are published in the scientific journal Nature Neuroscience, are of potential significance to the recovery of walking after spinal cord injury.

22 Jan 2010

ACS Chemical Biology report supports zebrafish for drug development

By combining the tools of medicinal chemistry and zebrafish biology, a team of Vanderbilt investigators has identified compounds that may offer therapeutic leads for bone-related diseases and cancer.

22 Jan 2010

BioTech Medics begins creating TV and radio commercials for SHBAN Alcohol Free Antiseptic Hand Sanitizer

BioTech Medics, Inc. announced today that they have begun the pre-production stage of creating two minute, sixty second and thirty second direct response TV and radio commercials for nationwide distribution for its proprietary SHBAN™ Alcohol Free Antiseptic Hand Sanitizer.

22 Jan 2010

Research shows frozen human eggs are as effective as fresh eggs to preserve fertility

Fertility specialists responsible for the first pregnancy in the Pacific Northwest resulting from frozen human eggs are hailing new research showing that frozen eggs can be as effective as fresh eggs in helping previously infertile women achieve pregnancy.

22 Jan 2010

AKD Global announces new class of cancer treatments in development

AKD Global announced today the discovery of a new class of cancer treatments in development, providing hope for millions of sufferers. The spectacular results demonstrate a highly potent effect on cancer cells with no toxicity to healthy tissue. AKD is raising funds to continue development.

22 Jan 2010

Study lays groundwork to develop new treatments for cardiovascular disease and other conditions

In a significant step toward restoring healthy blood circulation to treat a variety of diseases, a team of scientists at Weill Cornell Medical College has developed a new technique and described a novel mechanism for turning human embryonic and pluripotent stem cells into plentiful, functional endothelial cells, which are critical to the formation of blood vessels.

21 Jan 2010

Discovery of new class of compounds may help fight hepatitis C

Stanford University School of Medicine scientists have discovered a novel class of compounds that, in experiments in vitro, inhibit replication of the virus responsible for hepatitis C. If these compounds prove effective in infected humans as well, they may dramatically accelerate efforts to confront this virus’s propensity to rapidly acquire drug resistance, while possibly skirting some of the troubling side effects common among therapies in current use and in late-stage development.

21 Jan 2010

Dosing in First-in-Man Phase I study of 4SC AG's 4SC-203 commenced

4SC AG, a drug discovery and development company, today announced the start of dosing in a First-in-Man Phase I study in healthy volunteers evaluating 4SC-203, a novel multi-target kinase inhibitor, with particular specificity against selected kinases, including FMS-like tyrosine kinase 3 (FLT3), FLT3 mutants and vascular endothelial growth factor receptors (VEGF-R).

21 Jan 2010

Australia issues patent covering Kane Biotech's DispersinB anti-biofilm technology

Kane Biotech Inc., a biotechnology company engaged in the development of products that prevent and disperse microbial biofilms, is pleased to announce the issuance of Patent No. 2003284385 entitled "Compositions and methods for enzymatic detachment of bacterial and fungal biofilms" by IP Australia (Australian Patent and Trademark Office).

21 Jan 2010

VisEn Medical announces the commercial launch of new Cat B 680 FAST imaging agent

VisEn Medical Inc., a leader in fluorescence in vivo imaging from research through medicine, announced today the commercial launch of its new Cat B 680 FAST™ imaging agent for measuring and monitoring cathepsin B activity associated with disease progression and therapeutic response in vivo.

21 Jan 2010

New Life Agency announces creation of nation's first IVF insurance program

New Life Agency, Inc. today announced that it has joined forces with New Jersey-based The Diamond Institute IVF Center and Walgreens Specialty Pharmacy to create the nation's first IVF insurance program. The Assisted Reproduction Care (ARC) Insurance Program(SM) offers patients suffering from infertility feasible financial solutions for the ever-rising costs of In Vitro Fertilization (IVF) treatments, procedures and fertility medications.

20 Jan 2010

Gently rocking embryos during IVF may improve success rates

Gently rocking embryos while they grow during in vitro fertilization (IVF) improves pregnancy rates in mice by 22 percent, new University of Michigan research shows. The procedure could one day lead to significantly higher IVF success rates in humans.

20 Jan 2010

Alnylam Pharmaceuticals presents data on multiple therapeutic programs at RNAi Symposium

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today announced that it presented data from multiple pre-clinical and clinical programs at the “RNA Silencing: Mechanism, Biology, and Application” Keystone Symposium held January 14-19, 2010 in Keystone, Colorado. Alnylam and its collaborators presented data from Alnylam’s therapeutic programs including transthyretin (TTR)-mediated amyloidosis and Huntington’s disease, as well as new data on delivery approaches for the systemic delivery of RNAi therapeutics.

20 Jan 2010

iWorx launches a family of cardiovascular research products

iWorx, a developer of advanced physiology research and teaching tools, has launched a family of cardiovascular research products used to assess cardiac performance and hemodynamics, both in vivo and in vitro.

20 Jan 2010

Findings pave way for designing better antibiotics to target bacterial transcription machinery

A new study led by researchers at NYU Langone Medical Center is shedding new light on the action of Rho, a key regulatory protein in E. coli and many other bacteria.

19 Jan 2010

in vitro News and Research

Phadia's ImmunoCAP Rapid System receives FDA marketing clearance

Dynavax Technologies to present data on its SD-101 Phase 1b trial for chronic HCV infection

Long-term graft retention is improved through supplementation of fat grafts with ADRCs

Heart research news and updates from University of Houston

Injectable sealant found to be biocompatible and effective for fetal tissue repair

Findings offer potential significance to the recovery of walking after spinal cord injury

ACS Chemical Biology report supports zebrafish for drug development

BioTech Medics begins creating TV and radio commercials for SHBAN Alcohol Free Antiseptic Hand Sanitizer

Research shows frozen human eggs are as effective as fresh eggs to preserve fertility

AKD Global announces new class of cancer treatments in development

Study lays groundwork to develop new treatments for cardiovascular disease and other conditions

Discovery of new class of compounds may help fight hepatitis C

Dosing in First-in-Man Phase I study of 4SC AG's 4SC-203 commenced

Australia issues patent covering Kane Biotech's DispersinB anti-biofilm technology

VisEn Medical announces the commercial launch of new Cat B 680 FAST imaging agent

New Life Agency announces creation of nation's first IVF insurance program

Gently rocking embryos during IVF may improve success rates

Alnylam Pharmaceuticals presents data on multiple therapeutic programs at RNAi Symposium

iWorx launches a family of cardiovascular research products

Findings pave way for designing better antibiotics to target bacterial transcription machinery

Driving innovation in drug discovery with in vitro biology solutions eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News